METHOPRAZINE 50 MG
METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) : 50 MG · DIN 02238406 · AA PHARMA INC
Health Canada status: MARKETED
What is METHOPRAZINE?
METHOPRAZINE 50 MG contains METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02238406, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Apr-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is METHOPRAZINE used for?
METHOPRAZINE (Methotrimeprazine Maleate Tablets) is indicated for: Psychotic disturbances: acute and chronic schizophrenias, senile psychoses, manic-depressive syndromes. Analgesic: In pain due to cancer, zona, trigeminal neuralgia, neurocostal neuralgia, in phantom limb pains, muscular discomforts and as post-operative analgesic adjunct. Anti-emetic: For the treatment of nausea and vomiting of central origin. Sedative: For the management of insomnia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02238406 |
|---|---|
| Brand name | METHOPRAZINE |
| Generic / active ingredient | METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) : 50 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AA02 LEVOMEPROMAZINE |
| AHFS class | 28:16.08.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Apr-2014 |
| Original market date | 1998-07-20 00:00:00 |
How is it administered?
Adults: 6-25 mg/day (minor) or 50-75 mg/day (severe) in divided doses. Pediatrics (1-18y): 0.25 mg/kg daily. Adjust based on individual needs. Gradual withdrawal is advised.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Bottles of 100 and 500 tablets (for 2 mg, 5 mg, 25 mg, and 50 mg strengths)
Contraindications
Children <1 year; hypersensitivity to phenothiazines; coma/CNS depression; concomitant dopaminergics; blood dyscrasia; bone marrow depression; hepatic impairment; brain damage; pheochromocytoma.
Warnings and precautions
Increased mortality in elderly with dementia; Neuroleptic Malignant Syndrome (NMS); QT interval prolongation; orthostatic hypotension; venous thromboembolism; seizure threshold lowering.
What can be used instead?
Other Canadian products sharing ATC code N05AA02 LEVOMEPROMAZINE. 5 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| METHOPRAZINE | 2 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02238403 |
| METHOPRAZINE | 25 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02238405 |
| METHOPRAZINE | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02238404 |
| NOZINAN | 25 MG | SOLUTION | NEURAXPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 01927698 |
| METHOTRIMEPRAZINE-2 | 2 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239632 |
| METHOTRIMEPRAZINE-25 | 25 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239634 |
| METHOTRIMEPRAZINE-5 | 5 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239633 |
| METHOTRIMEPRAZINE-50 | 50 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02239635 |
| NOV MEPRAZINE TAB 50MG | 50 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 01964933 |
| NOVO MEPRAZINE TAB 25MG | 25 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 01964925 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.